Atherosclerosis - Pipeline Review, H1 2018

  • ID: 4473292
  • Drug Pipelines
  • 233 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • ChemoCentryx Inc
  • Esperion Therapeutics Inc
  • Inotrem SA
  • LG Chem Ltd
  • Shin Poong PharmCo Ltd
  • MORE
Atherosclerosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H1 2018, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 4, 47, 13 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 22 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AFFiRiS AG
  • ChemoCentryx Inc
  • Esperion Therapeutics Inc
  • Inotrem SA
  • LG Chem Ltd
  • Shin Poong PharmCo Ltd
  • MORE
Introduction

Atherosclerosis - Overview

Atherosclerosis - Therapeutics Development

Atherosclerosis - Therapeutics Assessment

Atherosclerosis - Companies Involved in Therapeutics Development

Atherosclerosis - Drug Profiles

Atherosclerosis - Dormant Projects

Atherosclerosis - Discontinued Products

Atherosclerosis - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Atherosclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018

Atherosclerosis - Pipeline by AFFiRiS AG, H1 2018

Atherosclerosis - Pipeline by Amgen Inc, H1 2018

Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H1 2018

Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2018

Atherosclerosis - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Atherosclerosis - Pipeline by Cardax Inc, H1 2018

Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H1 2018

Atherosclerosis - Pipeline by ChemoCentryx Inc, H1 2018

Atherosclerosis - Pipeline by CohBar Inc, H1 2018

Atherosclerosis - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Atherosclerosis - Pipeline by DoNatur GmbH, H1 2018

Atherosclerosis - Pipeline by Dybly AG, H1 2018

Atherosclerosis - Pipeline by Esperion Therapeutics Inc, H1 2018

Atherosclerosis - Pipeline by Forty Seven Inc, H1 2018

Atherosclerosis - Pipeline by GenKyoTex SA, H1 2018

Atherosclerosis - Pipeline by GlaxoSmithKline Plc, H1 2018

Atherosclerosis - Pipeline by Immusoft Corp, H1 2018

Atherosclerosis - Pipeline by Inotrem SA, H1 2018

Atherosclerosis - Pipeline by Inspyr Therapeutics Inc, H1 2018

Atherosclerosis - Pipeline by Iproteos SL, H1 2018

Atherosclerosis - Pipeline by KineMed Inc, H1 2018

Atherosclerosis - Pipeline by Kowa Co Ltd, H1 2018

Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2018

Atherosclerosis - Pipeline by LG Chem Ltd, H1 2018

Atherosclerosis - Pipeline by LipimetiX Development Inc, H1 2018

Atherosclerosis - Pipeline by MedImmune LLC, H1 2018

Atherosclerosis - Pipeline by Omeros Corp, H1 2018

Atherosclerosis - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Atherosclerosis - Pipeline by Shin Poong PharmCo Ltd, H1 2018

Atherosclerosis - Pipeline by The Medicines Company, H1 2018

Atherosclerosis - Pipeline by Tolerys SA, H1 2018

Atherosclerosis - Pipeline by Unity Biotechnology Inc, H1 2018

Atherosclerosis - Pipeline by Vascular Biogenics Ltd, H1 2018

Atherosclerosis - Pipeline by Vericel Corp, H1 2018

Atherosclerosis - Pipeline by Vicore Pharma AB, H1 2018

Atherosclerosis - Pipeline by XBiotech Inc, H1 2018

Atherosclerosis - Dormant Projects, H1 2018

Atherosclerosis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Atherosclerosis - Dormant Projects, H1 2018 (Contd..2), H1 2018

Atherosclerosis - Dormant Projects, H1 2018 (Contd..3), H1 2018

Atherosclerosis - Dormant Projects, H1 2018 (Contd..4), H1 2018

Atherosclerosis - Dormant Projects, H1 2018 (Contd..5), H1 2018

Atherosclerosis - Dormant Projects, H1 2018 (Contd..6), H1 2018

Atherosclerosis - Dormant Projects, H1 2018 (Contd..7), H1 2018

Atherosclerosis - Discontinued Products, H1 2018

Atherosclerosis - Discontinued Products, H1 2018 (Contd..1), H1 2018

Atherosclerosis - Discontinued Products, H1 2018 (Contd..2), H1 2018

List of Figures:

Number of Products under Development for Atherosclerosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ache Laboratorios Farmaceuticos SA
  • AFFiRiS AG
  • Amgen Inc
  • Annexin Pharmaceuticals AB
  • Athera Biotechnologies AB
  • Boehringer Ingelheim GmbH
  • Cardax Inc
  • Cerenis Therapeutics Holding SA
  • ChemoCentryx Inc
  • CohBar Inc
  • Daiichi Sankyo Co Ltd
  • DoNatur GmbH
  • Dybly AG
  • Esperion Therapeutics Inc
  • Forty Seven Inc
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Immusoft Corp
  • Inotrem SA
  • Inspyr Therapeutics Inc
  • Iproteos SL
  • KineMed Inc
  • Kowa Co Ltd
  • Lead Discovery Center GmbH
  • LG Chem Ltd
  • LipimetiX Development Inc
  • MedImmune LLC
  • Omeros Corp
  • Otsuka Holdings Co Ltd
  • Shin Poong PharmCo Ltd
  • The Medicines Company
  • Tolerys SA
  • Unity Biotechnology Inc
  • Vascular Biogenics Ltd
  • Vericel Corp
  • Vicore Pharma AB
  • XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll